{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:30Z","timestamp":1762542030629},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T00:00:00Z","timestamp":1327276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To discuss treatment modalities for aggressive posterior retinopathy of prematurity (AP\u2010ROP).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> The medical charts of all infants with AP\u2010ROP at Uppsala University Hospital, Sweden, during a 2\u2010year period (2009 and 2010) were reviewed. Eight infants (16 eyes) with a mean gestational age of 23.8\u2003weeks and a mean birth weight of 592\u2003g were treated with laser and\/or intravitreal injections of bevacizumab (0.4 and 0.625\u2003mg). RetCam photography was used to document the retinal appearance before and after treatment.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> All infants (16 eyes) had AP\u2010ROP in zone I. Mean time at initial treatment was 34\u2003weeks postmenstrual age. Two eyes (one infant) were only treated with laser, and six eyes (three infants) were treated with laser therapy or cryopexy and, because of lack of regression, with bevacizumab as salvage therapy. Eight eyes (four infants) were treated with a first\u2010line bevacizumab injection and four of these eyes (two infants) with additional laser ablation for continued disease progression in zone II. Macular dragging occurred in one eye of one infant primarily treated with laser.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Given the high complication rate of the extensive laser treatment for zone I ROP, it is worth considering anti\u2010vascular endothelial growth factor treatment as an alternative therapy. Further knowledge concerning side effects and long\u2010term ocular and systemic outcome is warranted before this drug becomes general clinical practice.<\/jats:p>","DOI":"10.1111\/j.1755-3768.2011.02351.x","type":"journal-article","created":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T12:01:31Z","timestamp":1327320091000},"page":"170-175","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?"],"prefix":"10.1111","volume":"91","author":[{"given":"Ulrich","family":"Spandau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Ewald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"\u00c5kerblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,23]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/157339909787314121"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.244"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.234"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.170704"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318169faee"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.09.012"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0661-y"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181ca1457"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181cb6151"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.12.1684"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.72"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1968.tb02813.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.771"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2007.11.009"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1103460"},{"key":"e_1_2_5_17_1","first-page":"[Epub ahead of","article-title":"Intravitreal bevacizumab for retinopathy of prematurity","author":"Harder BC","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0786-7"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2008.1"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000244285.79004.e6"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181644ad2"},{"key":"e_1_2_5_23_1","unstructured":"LeeSJ KimSY YooBB KimHW&KimYH(2011):Plasma level of vascular endothelial growth factor in retinopathy of prematurity after intravitreal injection of bevacizumab. ARVO Poster abstract. Program Number: 3165."},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.05.031"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.3129\/i10-027"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32832925f9"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318177f934"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4140"},{"key":"e_1_2_5_30_1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT\u2010ROP results into clinical practice","volume":"118","author":"Moshfeghi DM","year":"2011","journal-title":"Ophthalmology"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1395-3907.2003.00171.x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05291.x"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003554"},{"key":"e_1_2_5_34_1","first-page":"101","article-title":"Oxygen\u2010induced retinopathy in the mouse","volume":"35","author":"Smith LE","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.05.010"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.016"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.20092"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-3768.2011.02351.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-3768.2011.02351.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:25:29Z","timestamp":1697455529000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-3768.2011.02351.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,23]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/j.1755-3768.2011.02351.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02351.x","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,23]]},"assertion":[{"value":"2012-01-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}